Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 22nd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kalaris Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $18.75.

Kalaris Therapeutics Trading Down 1.5%

NASDAQ:KLRS opened at $2.00 on Friday. The stock has a market capitalization of $47.61 million, a PE ratio of -0.99 and a beta of 0.42. The firm’s 50 day moving average is $2.90 and its 200 day moving average is $5.41. Kalaris Therapeutics has a 12 month low of $1.78 and a 12 month high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. Research analysts predict that Kalaris Therapeutics will post -1.99 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Pale Fire Capital SE purchased a new stake in Kalaris Therapeutics in the second quarter worth $161,000. Velan Capital Investment Management LP raised its holdings in Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after purchasing an additional 7,000 shares in the last quarter. Sigma Planning Corp purchased a new position in Kalaris Therapeutics during the second quarter valued at $41,000. Stonepine Capital Management LLC purchased a new position in Kalaris Therapeutics during the second quarter valued at $122,597. Finally, ADAR1 Capital Management LLC purchased a new position in Kalaris Therapeutics during the second quarter valued at $407,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines.